Home > Press Releases
JST Press Release

Feb. 11, 2014
Japan Science and Technology Agency (JST)
5-3, Yonbancho, Chiyoda-ku, Tokyo 102-8666
URL http://www.jst.go.jp/EN/index.html

A Novel Therapeutic Oligonucleotide to Dramatically Enhance Vaccine Efficacy

We developed a novel complex made from therapeutic oligonucleotide CpG ODN and natural beta-glucan. When we applied this complex with influenza vaccine, immune stimulation due to the vaccine was dramatically increased for mice and monkey. This complex played a role of adjuvant and this technology can be used for a wide variety of field.

Researcher Information

Research Area : “Development of the foundation for nano-interface technology”
Research Theme : “Manipulation of nano interface of drug-delivery system and its application to vaccine for bird flu”

Journal Information

Published in “Proceedings of the National Academy of Sciences of the United States of America”


Kouji Kobiyamaa, Taiki Aoshi, Hirotaka Naritac, Etsushi Kurodab, Masayuki Hayashi, Kohhei Tetsutani, Shohei Koyamad, Shinichi Mochizuki, Kazuo Sakurai, Yuko Katakai, Yasuhiro Yasutomi,
Shinobu Saijoi, Yoichiro Iwakura, Shizuo Akira, Cevayir Coban, and Ken J. Ishii


“Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticlulate TLR9 agonist”
doi: 10.1073/pnas.1319268111


[About Research]
Ken Ishii, M.D., Ph.D.
Project Leader, Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation

Kazuo Sakurai Ph.D.
Professor, Faculty of Environmental Engineering, The University of Kitakyushu

[About Program]
Masashi Furukawa
Green Innovation Group, Department of Innovation Research, Japan Science and Technology Agency


JST, an integrated organization of science and technology in Japan, establishes an infrastructure for the entire process from the creation of knowledge to the return to the society. For more information, visit http://www.jst.go.jp/EN/